Outcome of pediatric patients with extracranial germ cell tumor, a single institutional experience, Egypt / Safaa AbdElhafeez Khaled ; Supervised Lobna M. Elamin Shalaby , Sahar Ahmed Khalil , Nesreen Magdy Mahmoud
Material type:
- نتائج علاج الاطفال المرض باورام الخلايا الجرثىمية خارج المخ بالمعهد القومي للأورام ، تجربة مؤسسة واحدة، مصر [Added title page title]
- Issued also as CD
Item type | Current library | Home library | Call number | Copy number | Status | Barcode | |
---|---|---|---|---|---|---|---|
![]() |
قاعة الرسائل الجامعية - الدور الاول | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2020.Sa.O (Browse shelf(Opens below)) | Not for loan | 01010110082739000 | ||
![]() |
مخـــزن الرســائل الجـــامعية - البدروم | المكتبة المركزبة الجديدة - جامعة القاهرة | Cai01.19.05.M.Sc.2020.Sa.O (Browse shelf(Opens below)) | 82739.CD | Not for loan | 01020110082739000 |
Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)
Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology
Introduction: Extracranial germ cell tumors are categorized as rare pediatric tumors. Childhood germ cell tumors (GCTs) are an assorted group of malignant and benign neoplasms that vary with respect to their clinical presentation, histopathology, and biologic characteristics, but are all believed to originate from primordial germ cells. Patient and methods: Among fifty eight eligible patients with extracranial germ cell tumor enroled from June 2011 to June 2017 who were treated according to Children{u2019}s Oncology Group (COG) protocol AGCT0132 which divided pediatric patients with germ cell tumors into three categories: low, intermediate, and high risk groups. Results: The 3- years overall survival (OS) was 86.2% with a median follow up period of 38.3 months (range from 0.3-96.7months) and 3-years event free survival (EFS) was 82.8% with median 36.1months (range from 0.1- 94.8months). The independent factor that significantly affect the overall survival was site of the primary [(gonadal vs extragonadal) (HR: 14.481, 95% CI: 1.761-119.063, p= 0. 013)] and pathological subtypes [(teratoma vs others) (HR: 8.210, 95% CI: 1.001-67.365, p=0.049)] and the independent factor that significantly affect the event-free survival were site of the primary [(gonadal vs extragonadal) (HR: 3.979, 95% CI: 1.027-15.406, p= 0. 046)] and pathological subtypes [(teratoma vs others) (HR: 6.508, 95% CI: 1.155-53.486, p=0.036)]
Issued also as CD
There are no comments on this title.